Another company has chosen to add Bitcoin (BTC) to its balance sheet.
Christian Angermeryer, president of the biopharmaceutical company based in Germany, Atai Life Sciences (ATAI), announced today that the company would develop its own Bitcoin treasure strategy.
“At a time of persistent inflation and volatile markets, I find myself asking an important question for biotechnology companies that seek to preserve and optimize the capital they have: could allocate part of Bitcoin Treasury money to help preserve, optimize and even extend the track of a company and therefore contribute to its success,” wrote Angermer.
The company will initially invest $ 5 million in Bitcoin, said Angermeryer, while having enough liquidity, short -term securities and public equity for operational expenses in 2027.
The pharmaceutical firm is the last of a long line of companies that have sought to reproduce the Bitcoin Cash Strategy by Michael Saylor.
Atai briefly jumped when the news broke out but is now down 2.8% for the day. After being briefly exceeded $ 87,000 overnight, Bitcoin was quickly retired, now changing hands at $ 83,900, down approximately 1% in the last 24 hours.
